U.S. Markets closed

Therapeutic Solutions International, Inc. (TSOI)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0565-0.0015 (-2.59%)
At close: 3:59PM EDT

Therapeutic Solutions International, Inc.

701 Wild Rose Lane
Elk City, ID 83525
United States
760 295 7208

Full Time Employees3

Key Executives

NameTitlePayExercisedYear Born
Mr. Timothy George DixonChairman, CEO & Pres220kN/A1958
Dr. Feng LinChief Scientific OfficerN/AN/A1969
Dr. James Drew Veltmeyer M.D.Chief Medical Officer, Vice Chairman of CTE Advisory Board & Member of Scientific Advisory BoardN/AN/A1964
Ms. Serena RobellaDirector of SalesN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases. The company develops a range of immune-modulatory agents to target cancers, improve maternal and fetal health, and fight periodontal disease, as well as for daily health. Its flagship products include NanoStilbene, an easily absorbed nanoemulsion of nanoparticle pterostilbene to reduce inflammatory cytokine production in cancer patients; and ProJuvenol, a synergistic blend of complex anti-aging ingredients. The company also focuses on the manufacture of devices to treat patients with obstructive sleep apnea. Therapeutic Solutions International, Inc. is based in Elk City, Idaho.

Corporate Governance

Therapeutic Solutions International, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.